-
cAMP kits
The large majority of receptors of interest for second-generation obesity drug discovery & development are Gs-coupled receptor, which makes cAMP quantification the most relevant and prevalent method of screening and characterization. Revvity carries a range of cAMP assays for all applications, including specific Gs assay adapted to the pharmacology of these GPCRs:
- HTRF cAMP Gs Dynamic for increased sensitivity
- HTRF cAMP Gs HiRange for wider assay windows
- HTRF cAMP Gi
- LANCE Ultra cAMP
-
IP-One kits
Many Gs-coupled receptor, including GLP-1R & GIPR, have secondary Gq coupling that accounts for subtle variation between ligands. Adding that layer of characterization to drug candidates is relevant to the fine-tuning that this new generation of molecules calls for.
Fontaine, T., Busch, A., Laeremans, T. et al. Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist. Nat Commun 15, 7029 (2024).
- HTRF IP-One
- AlphaLISA IP-One for increased sensitivity & wider assay window
-
Beta-arrestins Kits
Beta-arrestin recruitment & receptor internalization appears to be an important characteristic of successful molecules so far, with scientists suggesting lignad bias is key to the design of fine-tuned drug candidates. For instance, the dual GLP-1R/GIPR agonist Tirzepatide shows native ligand-like signaling at GIPR in terms of G-protein signaling and beta-arrestin recruitment, but exhibits a strong bias toward G-protein signaling at GLP-1R, where the recruitment of arrestin and receptor internalization are much less promoted. Revvity offers several beta-arrestin assays, including a beta-arrestin recruitment solution designed to study ligand bias in endogeneous beta-arrestin expression level settings.
-
Tag-lite binding assay kits
Tag-lite is a non-radioactive, cell-based technology that enables the investigation of natural ligands, small molecules or antibodies binding to cell surface receptors. It is especially advantageous for GPCR and, as well as for the study of real-time ligand kinetics.
SNAP-tag receptor expressing cell line
Ready to use binding assay reagents
- GLP1 receptor Frozen & Labeled Cells
- GIP receptor Frozen & Labeled Cells
- GLP1 receptor Red Agonist Ligand
- GIP receptor Red Agonist Ligand
Transfect your cells of choice with SNAP-tagged receptors
-
Phospho assay kits
The transduction of Gi and Gs-coupled Receptor-dependent downstream signals is operated by phosphorylation cascades under the regulation of cAMP levels via PKA activation/inhibition. These cascades are varied and branch out into an array of pathways that depends on the receptor initiating the signal, cell types, tissues, etc. Revvity offers a rich portfolio of cell signaling assays with over 150 analytes to study complex signaling pathways at every step of their phosphorylation cascade. Among these, a few phosphoproteins are consistently involved in the early stages of GPCR signaling and add a layer of characterization when designing finely-tuned ligands candidates fro Obesity treatment.
- ERK1/2 Detection Kits (Phospho Thr202/Tyr204 & Total)
- CREB Detection Kits (Phospho Ser133 & Total)
- CC-RAF Detection Kits (Phospho Ser338 & Total)
Diabetes: assays tailored for insulin and glucagon studies
Revvity focuses on providing assays that help cover your needs and make research more straightforward. With our kits, everything stays in focus:
- Ultra-sensitive and high-range insulin assays covering a dynamic range from 0.004 ng/mL to 150 ng/mL
- Diverse and relevant models, such as human, rat, mouse, and pig, for insulin and glucagon assays
Metabolic disorders
Revvity enables you to explore the world of metabolic disorders with reliable and easy-to-use immunoassays based on HTRF™ and Alpha™ technologies. We are dedicated to helping scientists discover new therapies and have developed many assays to reach that exact objective!
Whether you work on fibrosis, psoriasis, obesity, or any other disorder, it is very likely you will find what you need in our assay line, ranging from target identification and screening to pre-clinical sample testing. See our catalog for complete descriptions.


Featured resources
References
- https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
- Jones B,et al. In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist. Diabetes Obes Metab. 2022 Nov;24(11):2090-2101. doi: 10.1111/dom.14794. Epub 2022 Jul 18. PMID: 35676825; PMCID: PMC9796023.
- Lucey M, et al. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists. Mol Metab. 2020 Jul;37:100991. doi: 10.1016/j.molmet.2020.100991. Epub 2020 Apr 8. PMID: 32278079; PMCID: PMC7262448.
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, Volume 34, Issue 9, 1234 - 1247.e9. c. doi: j.cmet.2022.07.013
- McGlone E.R et al. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity. Biomedicine & Pharmacotherapy, Volume 176, 2024. https://doi.org/10.1016/j.biopha.2024.116888
- Fontaine, T., Busch, A., Laeremans, T. et al. Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist. Nat Commun 15, 7029 (2024). https://doi.org/10.1038/s41467-024-50827-7
- Chichura, K.S., Elfers, C.T., Salameh, T.S. et al. A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss. Sci Rep 13, 9554 (2023). https://doi.org/10.1038/s41598-023-36178-1
- Roed SN, et al. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Mol Cell Endocrinol. 2014 Feb 15;382(2):938-49. doi: 10.1016/j.mce.2013.11.010. Epub 2013 Nov 22. PMID: 24275181.